Back to feed

NCT05748834

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 2 Single Arm Trial With a Safety Lead-in of Tucatinib in Combination With Doxil for the Treatment of HER2+ Metastatic Breast Cancer

ClinicalTrials.gov
Sponsor
SCRI Development Innovations, LLC
Status
Recruiting
Versions
10
Adjacent patches
9
Severity is deterministic, reproducible, uncalibrated triage metadata, not validated review priority or proven wrongdoing. New Evidence Record packages are generated for deterministic event-class membership, not by triage rank alone.

Material event timeline

5 shown
Triage: Medium
2023-05-08
Timeline Significant Shift
v0 to v1 Pre Recruitment Inspect patch
/protocolSection/statusModule/lastUpdatePostDateStruct/date
/protocolSection/statusModule/lastUpdateSubmitDate
/protocolSection/statusModule/startDateStruct/date
Triage: Medium
2023-07-17
Timeline Shift
v2 to v3 Early Recruitment Inspect patch
/protocolSection/statusModule/lastUpdatePostDateStruct/date
/protocolSection/statusModule/lastUpdateSubmitDate
/protocolSection/statusModule/startDateStruct/date
Triage: Low
2023-08-01
Timeline Actualized Earlier
v3 to v4 Early Recruitment Inspect patch
/protocolSection/statusModule/lastUpdatePostDateStruct/date
/protocolSection/statusModule/lastUpdateSubmitDate
/protocolSection/statusModule/startDateStruct/date
Triage: Low
2024-01-22
Administrative Contact Change
v4 to v5 Early Recruitment Inspect patch
/protocolSection/contactsLocationsModule/centralContacts/0/email
/protocolSection/contactsLocationsModule/centralContacts/0/phone
/protocolSection/contactsLocationsModule/locations/0/contacts
Triage: High
2026-03-17
Eligibility Change
v8 to v9 Early Recruitment Inspect patch
/protocolSection/eligibilityModule/eligibilityCriteria
/protocolSection/oversightModule/isUsExport
/protocolSection/statusModule/completionDateStruct/date